MG
MCID: MYS003
MIFTS: 67

Myasthenia Gravis (MG) malady

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Myasthenia Gravis

Aliases & Descriptions for Myasthenia Gravis:

Name: Myasthenia Gravis 38 12 50 25 51 56 29 52 41 42 14 69
Autoimmune Myasthenia Gravis 56
Acquired Myasthenia 56
Mg 25

Characteristics:

Orphanet epidemiological data:

56
myasthenia gravis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (Worldwide),1-9/1000000 (United States),1-5/10000 (Canada),1-9/100000 (Spain),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/100000 (Serbia),1-5/10000 (United States),1-5/10000 (Serbia),1-9/100000 (Italy),1-5/10000 (Austria),1-9/100000 (Australia),1-5/10000 (Italy),1-9/100000 (Taiwan, Province of China),1-5/10000 (Australia),1-9/1000000 (Greece),1-5/10000 (Taiwan, Province of China),1-9/1000000 (Croatia),1-9/100000 (Estonia),1-9/100000 (Greece),1-9/100000 (Croatia),1-9/100000 (Egypt),1-9/1000000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:437
ICD10 33 G70.0 G70.00
ICD9CM 35 358.0 358.00
MeSH 42 D009157
NCIt 47 C60989
Orphanet 56 ORPHA589
ICD10 via Orphanet 34 G70.0
MESH via Orphanet 43 D009157
UMLS via Orphanet 70 C0026896

Summaries for Myasthenia Gravis

NINDS : 51 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, which are responsble for breathing and moving parts of the body. In myasthenia gravis, the immune system--which normally protects the body from foreign organisms--mistakenly attacks itself.  Symptoms vary in type and intensity. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Certain muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Other symptoms may include blurred or double vision, drooping eyelid(s), and weakness in the arms, hands, fingers, legs, and neck. Myasthenia gravis is not directly inherited nor is it contagious.

MalaCards based summary : Myasthenia Gravis, also known as autoimmune myasthenia gravis, is related to hepatitis and autoimmune hemolytic anemia, and has symptoms including dyspnea, seizures and ophthalmoparesis. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways/superpathways are Allograft rejection and Immune response NFAT in immune response. The drugs Azathioprine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include eye, thymus and skeletal muscle, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and behavior/neurological

Genetics Home Reference : 25 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.

NIH Rare Diseases : 50 myasthenia gravis (mg) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles of the body. common symptoms include weakness of the muscles that control the eye and eyelid; facial expressions; chewing; talking; and swallowing. weakness tends to increase during periods of activity and improves after periods of rest. myasthenia gravis results from a defect in the transmission of nerve impulses to muscles, due to the presence of antibodies against the acetylcholine. however, the exact cause is unknown. some cases have been linked to tumors in the thymus gland. researchers believe that variations in certain genes may increase a person's risk to develop this condition, but it is likely that other factors also play a role. there is no cure for myasthenia gravis yet, but treatment can significantly improve muscle weakness. some case of myasthenia gravis may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued. last updated: 2/23/2017

MedlinePlus : 41 myasthenia gravis is a disease that causes weakness in your voluntary muscles. these are the muscles that you control. for example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. you can also have weakness in other muscles. this weakness gets worse with activity, and better with rest. myasthenia gravis is an autoimmune disease. your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. this makes your muscles weaker. other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. with treatment, the muscle weakness often gets much better. medicines can help improve nerve-to-muscle messages and make muscles stronger. other drugs keep your body from making so many abnormal antibodies. these medicines can have major side effects, so they should be used carefully. there are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. sometimes, surgery to take out the thymus gland helps. some people with myasthenia gravis go into remission. this means that they do not have symptoms. the remission is usually temporary, but sometimes it can be permanent. nih: national institute of neurological disorders and stroke

Wikipedia : 71 Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal... more...

Related Diseases for Myasthenia Gravis

Diseases in the Myasthenia Gravis family:

Myasthenia Gravis Congenital Juvenile Myasthenia Gravis
Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 452)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.9 CTLA4 IFNG IL10 IL2 TNF
2 autoimmune hemolytic anemia 29.5 CTLA4 IFNG IL2
3 exophthalmos 29.5 IFNG IL10 IL2 IL4 TNF
4 tuberculosis 29.5 IL10 IL2 IL4 TNF
5 rheumatoid arthritis 29.0 CTLA4 IFNG IL10 IL2 IL4 TNF
6 articulation disorder 28.2 CTLA4 IFNG IL10 IL2 IL4 MBP
7 juvenile myasthenia gravis 12.3
8 transient neonatal myasthenia gravis 12.3
9 adult-onset myasthenia gravis 12.3
10 neonatal myasthenia gravis 12.2
11 rippling muscle disease with myasthenia gravis 12.2
12 myasthenia gravis with thymus hyperplasia 12.2
13 myasthenia gravis congenital 12.1
14 myasthenia gravis, limb-girdle 12.0
15 thymoma 11.6
16 congenital myasthenic syndrome 11.6
17 neuromuscular disease 11.6
18 rippling muscle disease 11.4
19 paraneoplastic syndromes 11.4
20 autoimmune oophoritis 11.4
21 autoimmune polyglandular syndrome type 3 11.4
22 dysphagia 11.4
23 myasthenic syndrome, congenital, 6, presynaptic 11.2
24 escobar syndrome 11.0
25 paraneoplastic neurologic disorders 11.0
26 thymus cancer 11.0
27 swallowing disorders 11.0
28 myasthenic syndrome, congenital, 10 11.0
29 lambert-eaton myasthenic syndrome 10.4
30 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
31 mycobacterium marinum 10.3 CHRNG RAPSN
32 congenital rubella 10.3 CHRNE RAPSN
33 pemphigus 10.3
34 multiple pterygium syndrome, lethal type 10.3 CHRNA1 CHRNE
35 thymic hyperplasia 10.3
36 mitochondrial complex iii deficiency, nuclear type 2 10.3 CHRNE MUSK RAPSN
37 steatitis 10.3 IL2 TNF
38 lupus erythematosus 10.2
39 low anorectal malformation 10.2 CTLA4 IL10 TNF
40 parkinson disease 11 10.2 IFNG IL10 TNF
41 senile reticular retinal degeneration 10.2 IFNG IL10 TNF
42 conduct disorder 10.2 IFNG IL10 TNF
43 pancreatic signet ring cell adenocarcinoma 10.2 IFNG IL10 TNF
44 pulpitis 10.2 IFNG IL10 TNF
45 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 IL4 TNF
46 tooth agenesis, selective, 1, with or without orofacial cleft 10.2 CHRNA1 CHRNG MUSK RAPSN
47 hereditary alpha tryptasemia syndrome 10.2 IFNG IL10 TNF
48 rickettsialpox 10.2 IFNG IL10 TNF
49 lagophthalmos 10.2 IL10 IL4 TNF
50 erb-duchenne and dejerine-klumpke palsies 10.2 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to Myasthenia Gravis

Symptoms & Phenotypes for Myasthenia Gravis

Human phenotypes related to Myasthenia Gravis:

56 32 (show all 28)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dyspnea 56 32 Frequent (79-30%) HP:0002094
2 seizures 56 32 Very rare (<4-1%) HP:0001250
3 ophthalmoparesis 56 32 Frequent (79-30%) HP:0000597
4 hyperacusis 56 32 Occasional (29-5%) HP:0010780
5 ptosis 56 32 Frequent (79-30%) HP:0000508
6 diplopia 56 32 Frequent (79-30%) HP:0000651
7 dysarthria 56 32 Frequent (79-30%) HP:0001260
8 dysphagia 56 32 Frequent (79-30%) HP:0002015
9 hearing impairment 56 32 Occasional (29-5%) HP:0000365
10 acrocyanosis 56 32 Very rare (<4-1%) HP:0001063
11 hepatitis 56 32 Very rare (<4-1%) HP:0012115
12 hemolytic anemia 56 32 Very rare (<4-1%) HP:0001878
13 hashimoto thyroiditis 56 32 Occasional (29-5%) HP:0000872
14 hyperthyroidism 56 32 Occasional (29-5%) HP:0000836
15 paresthesia 56 32 Occasional (29-5%) HP:0003401
16 primary adrenal insufficiency 56 32 Occasional (29-5%) HP:0008207
17 psychosis 56 32 Very rare (<4-1%) HP:0000709
18 myositis 56 32 Frequent (79-30%) HP:0100614
19 abnormality of the thymus 56 32 Frequent (79-30%) HP:0000777
20 bulbar palsy 56 32 Frequent (79-30%) HP:0001283
21 single fiber emg abnormality 56 32 Frequent (79-30%) HP:0030006
22 acetylcholine receptor antibody positivity 56 32 Frequent (79-30%) HP:0030208
23 muscle specific kinase antibody positivity 56 32 Frequent (79-30%) HP:0030210
24 rheumatoid arthritis 56 32 Occasional (29-5%) HP:0001370
25 systemic lupus erythematosus 56 32 Occasional (29-5%) HP:0002725
26 glycosuria 56 32 Occasional (29-5%) HP:0003076
27 pure red cell aplasia 56 32 Very rare (<4-1%) HP:0012410
28 muscle weakness 56 Very frequent (99-80%)

UMLS symptoms related to Myasthenia Gravis:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, muscle weakness, facial paresis, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.17 TMPO
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.17 TMPO
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 9.17 CHRNA1 RAPSN TMPO
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.17 TMPO
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.17 TMPO

MGI Mouse Phenotypes related to Myasthenia Gravis:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 TTN AGRN AKAP12 CHRNA1 CHRNE CHRNG
2 growth/size/body region MP:0005378 10.31 ACHE AGRN CHRNE CHRNG IFNG IL10
3 homeostasis/metabolism MP:0005376 10.3 IL10 IL2 IL4 MBP MUSK RAPSN
4 mortality/aging MP:0010768 10.3 ACHE AGRN AKAP12 CHRNA1 CHRNE CHRNG
5 hematopoietic system MP:0005397 10.22 ACHE AKAP12 CTLA4 IFNG IL10 IL2
6 digestive/alimentary MP:0005381 10.11 CTLA4 IFNG IL10 IL2 IL4 RYR1
7 muscle MP:0005369 10.1 AGRN AKAP12 CHRNE CHRNG IFNG IL10
8 integument MP:0010771 10.09 TMPO TNF CHRNG CTLA4 IFNG IL10
9 craniofacial MP:0005382 10.07 TTN ACHE IFNG IL10 IL4 RYR1
10 nervous system MP:0003631 10.07 ACHE AGRN AKAP12 CHRNA1 CHRNE CHRNG
11 respiratory system MP:0005388 10 ACHE AGRN AKAP12 CHRNE CHRNG CTLA4
12 liver/biliary system MP:0005370 9.95 AKAP12 CTLA4 IFNG IL10 IL2 IL4
13 skeleton MP:0005390 9.61 CHRNA1 CTLA4 IFNG IL10 IL4 MUSK
14 vision/eye MP:0005391 9.23 ACHE IFNG IL10 IL2 IL4 MBP

Drugs & Therapeutics for Myasthenia Gravis

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
2
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
3 Antimetabolites Phase 4,Phase 3,Phase 2
4 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
5 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 glucocorticoids Phase 4,Phase 3
7 Hormone Antagonists Phase 4,Phase 3
8 Hormones Phase 4,Phase 3
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
10 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
11 Antibodies Phase 4,Phase 3,Phase 2
12 gamma-Globulins Phase 4,Phase 3,Phase 2
13 Immunoglobulins Phase 4,Phase 3,Phase 2
14 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
15 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
16 Anti-Inflammatory Agents Phase 4,Phase 3
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3
18
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
19
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
20
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
21
Mycophenolic acid Approved Phase 3 24280-93-1 446541
22
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
24
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492
25
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
26
Rocuronium Approved Phase 3 119302-91-9, 143558-00-3 441290
27
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
28
Aluminum hydroxide Approved Phase 2, Phase 3,Phase 1 21645-51-2
29 tannic acid Approved, Nutraceutical Phase 3
30 Cholinergic Agents Phase 3,Phase 1,Phase 2
31 Cholinesterase Inhibitors Phase 3
32 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
33 Pyridostigmine Bromide Phase 3 101-26-8
34 Anti-Bacterial Agents Phase 3
35 Antibiotics, Antitubercular Phase 3
36 Methylprednisolone acetate Phase 3
37 Methylprednisolone Hemisuccinate Phase 3
38 Prednisolone acetate Phase 3
39 Prednisolone hemisuccinate Phase 3
40 Prednisolone phosphate Phase 3
41 Calcineurin Inhibitors Phase 3
42 Vaccines Phase 3,Phase 1,Phase 2
43 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
44 3,4-diaminopyridine Phase 3
45 Potassium Channel Blockers Phase 3
46 Neuromuscular Agents Phase 3
47 Neuromuscular Blocking Agents Phase 3
48 Neuromuscular Nondepolarizing Agents Phase 3
49 Peripheral Nervous System Agents Phase 3
50 Bromides Phase 3

Interventional clinical trials:

(show top 50) (show all 71)
id Name Status NCT ID Phase
1 Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis Completed NCT01179893 Phase 4
2 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Active, not recruiting NCT00987116 Phase 4
3 The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Unknown status NCT01727193 Phase 3
4 Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis Completed NCT00306033 Phase 3
5 Mycophenolate Mofetil in Myasthenia Gravis Completed NCT00285350 Phase 3
6 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3
7 Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Completed NCT00515450 Phase 3
8 A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis Completed NCT01325571 Phase 3
9 Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) Completed NCT01997229 Phase 3
10 FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients Completed NCT00309088 Phase 3
11 A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis. Completed NCT00408213 Phase 3
12 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Completed NCT00683969 Phase 3
13 An Open Study for Steroid Resistant, Non-Thymectomized MG Patients Completed NCT00309101 Phase 3
14 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3
15 Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest Completed NCT01719770 Phase 3
16 A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis Recruiting NCT02950155 Phase 3
17 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Recruiting NCT02413580 Phase 3
18 A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Recruiting NCT02774239 Phase 3
19 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Recruiting NCT02970162 Phase 3
20 ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis Active, not recruiting NCT02301624 Phase 3
21 A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis Not yet recruiting NCT03165435 Phase 2, Phase 3
22 Efficacy of Prednisone In the Treatment of Ocular Myasthenia Terminated NCT00995722 Phase 3
23 Efficacy of Methotrexate in Myasthenia Gravis Completed NCT00814138 Phase 2
24 A Pilot Trial of Rituxan in Refractory Myasthenia Gravis Completed NCT00619671 Phase 1, Phase 2
25 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2
26 The Evaluation of Belimumab in Myasthenia Gravis (MG) Completed NCT01480596 Phase 2
27 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis. Recruiting NCT03052751 Phase 2
28 Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis Recruiting NCT02565576 Phase 2
29 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Recruiting NCT02100969 Phase 2
30 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Recruiting NCT02965573 Phase 2
31 Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Recruiting NCT02473965 Phase 2
32 A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis Recruiting NCT02473952 Phase 2
33 The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor Recruiting NCT02317224 Phase 2
34 Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Recruiting NCT02102594 Phase 2
35 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Recruiting NCT03174964 Phase 2
36 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Recruiting NCT03174951 Phase 2
37 BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Active, not recruiting NCT02110706 Phase 2
38 Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis Active, not recruiting NCT02609022 Phase 1, Phase 2
39 Sulfamethoxazole for the Treatment of Primary PREPL Deficiency Enrolling by invitation NCT02640443 Phase 2
40 Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Terminated NCT00727194 Phase 2
41 Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis Terminated NCT01268280 Phase 2
42 Exercise for Stable Myasthenia Gravis Recruiting NCT01047761 Phase 1
43 Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis Terminated NCT00424489 Phase 1
44 A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis Unknown status NCT01555580 Early Phase 1
45 Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis Unknown status NCT00997412
46 The Effect of Erythromycin on Occurrence of Leaks From Cervical Esophageal-Gastric Anastomosis After Trans-Hiatal Esophagectomy Unknown status NCT00373919
47 Inherited Myokymia: A Clinical and Genetic Study of a Family Unknown status NCT01250704
48 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
49 Therapeutic Plasma Exchange in MG Completed NCT01927692
50 Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F Completed NCT02470364

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: myasthenia gravis

Genetic Tests for Myasthenia Gravis

Genetic tests related to Myasthenia Gravis:

id Genetic test Affiliating Genes
1 Myasthenia Gravis 29

Anatomical Context for Myasthenia Gravis

MalaCards organs/tissues related to Myasthenia Gravis:

39
Eye, Thymus, Skeletal Muscle, Testes, T Cells, B Cells, Thyroid

Publications for Myasthenia Gravis

Articles related to Myasthenia Gravis:

(show top 50) (show all 1437)
id Title Authors Year
1
Thymectomy and myasthenia gravis: A history of surgical passion and scientific excellence. ( 28479053 )
2017
2
Fatal Morvan Syndrome Associated With Myasthenia Gravis. ( 28009770 )
2017
3
HLA and age of onset in myasthenia gravis. ( 28495048 )
2017
4
Transient neonatal myasthenia gravis due to a mother with ocular onset of anti-muscle specific kinase myasthenia gravis. ( 28495046 )
2017
5
Anesthetic Management of a Patient With Antimuscle-Specific Kinase Antibody-Positive Myasthenia Gravis Undergoing an Open Cholecystectomy: A Case Report. ( 28079665 )
2017
6
Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. ( 28516329 )
2017
7
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. ( 28505981 )
2017
8
A possible role of low regulatory T cells in anti-acetylcholine receptor antibody positive myasthenia gravis after bone marrow transplantation. ( 28506261 )
2017
9
GVHD-like erythroderma in the clinical course of thymoma-associated myasthenia gravis. ( 28524043 )
2017
10
Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. ( 28087666 )
2017
11
Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients. ( 28045063 )
2017
12
Validity of Forced Eyelid Closure Test: A Novel Clinical Screening Test for Ocular Myasthenia Gravis. ( 28492464 )
2017
13
Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis. ( 28494776 )
2017
14
Exercise in myasthenia gravis: A feasibility study of aerobic and resistance training. ( 28085204 )
2017
15
Robotic thymectomy for myasthenia gravis with or without thymoma-surgical and neurological outcomes. ( 28084239 )
2017
16
Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis. ( 28523463 )
2017
17
I^2-Adrenergic receptor gene polymorphisms in the relapse of myasthenia gravis with thymus abnormality. ( 27338803 )
2017
18
Randomized Trial of Thymectomy in Myasthenia Gravis. ( 28471717 )
2017
19
Analysis of mortality and related factors in 2195 adult myasthenia gravis patients in a 10-year follow-up study. ( 28488612 )
2017
20
Frame-shift variant in the CHRNE gene in a juvenile dog with suspected myasthenia gravis-like disease. ( 28508416 )
2017
21
Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis. ( 28488158 )
2017
22
TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis. ( 28514294 )
2017
23
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis. ( 28075449 )
2017
24
A quantitative method for the assessment of dysarthrophonia in myasthenia gravis. ( 28477705 )
2017
25
Selective or predominant triceps muscle weakness in African-American patients with myasthenia gravis. ( 28495049 )
2017
26
Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis. ( 28516744 )
2017
27
Myasthenia Gravis and Its Aeromedical Implications. ( 28061919 )
2017
28
Myasthenia Gravis, Mediastinal Goiter, and Crohn's Disease. ( 28528037 )
2017
29
Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel. ( 28495138 )
2017
30
miR-20b Inhibits T Cell Proliferation and Activation via NFAT Signaling Pathway in Thymoma-Associated Myasthenia Gravis. ( 27833920 )
2016
31
Myasthenia Gravis. ( 28029925 )
2016
32
Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma. ( 26818174 )
2016
33
Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms. ( 27609276 )
2016
34
Ocular Myasthenia Gravis in Monozygotic Twins with Mirror-image Myopic Anisometropia. ( 27729761 )
2016
35
Temporal deterioration of neurological symptoms and increase of serum acetylcholine receptor antibody levels after thymectomy: a case report of a cat with myasthenia gravis. ( 27593682 )
2016
36
HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients. ( 27000234 )
2016
37
Gene-Specific Methylation Analysis in Thymomas of Patients with Myasthenia Gravis. ( 27999265 )
2016
38
Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. ( 27181991 )
2016
39
Curcumin ameliorates experimental autoimmune myasthenia gravis by diverse immune cells. ( 27181511 )
2016
40
Paroxysmal supraventricular tachycardia in anti-musk Myasthenia gravis: A case report. ( 27653899 )
2016
41
Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab. ( 27408396 )
2016
42
Myopathic changes detected by quantitative electromyography in patients with MuSK and AChR positive myasthenia gravis. ( 26778359 )
2016
43
Thymectomy for myasthenia gravis: what we know and what we don't. ( 28066568 )
2016
44
Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis. ( 25962782 )
2016
45
Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis. ( 27170368 )
2016
46
Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma. ( 27076925 )
2016
47
Catastrophes during video-assisted thoracoscopic thymus surgery for myasthenia gravis. ( 27199379 )
2016
48
Analysis of TNF-related apoptosis-inducing ligand and receptors and implications in thymus biology and myasthenia gravis. ( 28012741 )
2016
49
Changes in inflammatory cytokine networks in myasthenia gravis. ( 27172995 )
2016
50
Myasthenia gravis accompanied by Graves' disease, thyrotoxic hypokalemic periodic paralysis and thymic hyperplasia. ( 27381127 )
2016

Variations for Myasthenia Gravis

Expression for Myasthenia Gravis

Search GEO for disease gene expression data for Myasthenia Gravis.

Pathways for Myasthenia Gravis

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 36)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 CTLA4 IFNG IL10 IL2 IL4 TNF
2
Show member pathways
12.6 IFNG IL10 IL2 IL4 TNF
3
Show member pathways
12.55 IFNG IL10 IL2 IL4 TNF
4
Show member pathways
12.37 CTLA4 IFNG IL10 IL2 IL4 TNF
5
Show member pathways
12.3 IFNG IL2 IL4 TNF
6 12.3 CTLA4 IFNG IL10 IL2 IL4 TNF
7
Show member pathways
12.22 IFNG IL10 IL4 TNF
8
Show member pathways
12.18 IFNG IL10 IL2 IL4
9
Show member pathways
12.1 IFNG IL10 IL2 IL4 TNF
10 11.92 IFNG IL10 IL2 IL4 TNF
11
Show member pathways
11.91 IFNG IL10 IL2 TNF
12 11.83 CTLA4 IFNG TNF TNFSF13B
13
Show member pathways
11.77 CHRNA1 CHRNE CHRNG
14 11.76 IFNG IL2 IL4
15 11.75 IFNG IL10 IL2 TNF
16 11.67 IFNG IL10 IL2 IL4 TNF
17 11.66 IFNG IL10 IL2
18
Show member pathways
11.63 IFNG IL2 TNF
19
Show member pathways
11.61 IFNG IL2 TNF
20 11.6 AGRN CHRNA1 MUSK RAPSN
21
Show member pathways
11.6 CTLA4 IFNG IL2 IL4 TNF
22 11.52 IFNG IL2 TNF
23 11.51 IFNG IL2 IL4 MBP TNF TNFSF13B
24 11.49 IL10 IL4 TNF
25 11.49 IFNG IL10 TNF
26 11.48 IFNG IL10 IL2 IL4
27 11.47 IFNG IL2 TNF
28 11.4 CTLA4 IL10 IL4 TNF TNFSF13B
29
Show member pathways
11.34 IFNG IL10 IL2 TNF
30 11.33 IFNG IL10 TNF
31 11.29 IFNG IL2 IL4
32 11.27 IFNG IL4 TNF
33 11.19 IL10 IL2 IL4 TNF TNFSF13B
34 11.12 IFNG IL10 IL2 IL4
35 10.79 CHRNA1 CHRNE RYR1
36 10.5 IFNG IL10 IL2 IL4 TNF

GO Terms for Myasthenia Gravis

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.87 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK
2 external side of plasma membrane GO:0009897 9.71 CTLA4 IFNG IL4 TNF
3 postsynaptic membrane GO:0045211 9.65 CHRNA1 CHRNE CHRNG MUSK RAPSN
4 acetylcholine-gated channel complex GO:0005892 9.33 CHRNA1 CHRNE CHRNG
5 neuromuscular junction GO:0031594 9.26 ACHE CHRNA1 MUSK RAPSN
6 synapse GO:0045202 9.17 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK
7 plasma membrane GO:0005886 10.18 ACHE AGRN AKAP12 CHRNA1 CHRNE CHRNG
8 extracellular region GO:0005576 10.09 ACHE AGRN IFNG IL10 IL2 IL4

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 cation transmembrane transport GO:0098655 9.82 CHRNA1 CHRNE CHRNG
2 excitatory postsynaptic potential GO:0060079 9.81 CHRNA1 CHRNE CHRNG
3 muscle contraction GO:0006936 9.81 CHRNE CHRNG RYR1 TTN
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 IFNG IL2 IL4
5 regulation of postsynaptic membrane potential GO:0060078 9.77 CHRNA1 CHRNE CHRNG
6 response to nicotine GO:0035094 9.77 CHRNA1 CHRNE CHRNG
7 positive regulation of protein phosphorylation GO:0001934 9.77 IFNG IL2 IL4 MUSK TNF
8 positive regulation of B cell proliferation GO:0030890 9.72 IL2 IL4 TNFSF13B
9 positive regulation of T cell proliferation GO:0042102 9.71 IFNG IL2 IL4 TNFSF13B
10 neuromuscular synaptic transmission GO:0007274 9.67 CHRNA1 CHRNE CHRNG
11 negative regulation of nitric oxide biosynthetic process GO:0045019 9.65 IL10 IL4
12 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL10 TNF
13 skeletal muscle acetylcholine-gated channel clustering GO:0071340 9.63 MUSK RAPSN
14 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.63 IL10 MBP
15 defense response to protozoan GO:0042832 9.63 IFNG IL10 IL4
16 endothelial cell apoptotic process GO:0072577 9.62 IL10 TNF
17 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 IL10 TNF
18 type 2 immune response GO:0042092 9.61 IL10 IL4
19 negative regulation of growth of symbiont in host GO:0044130 9.61 IFNG IL10 TNF
20 regulation of isotype switching GO:0045191 9.58 IL10 IL4
21 negative regulation of T-helper 17 cell differentiation GO:2000320 9.58 IL2 IL4
22 B cell costimulation GO:0031296 9.57 IL4 TNFSF13B
23 positive regulation of mononuclear cell migration GO:0071677 9.56 IL4 TNF
24 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 IFNG TNF
26 positive regulation of chemokine biosynthetic process GO:0045080 9.5 IFNG IL4 TNF
27 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
28 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 IFNG IL2 IL4
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.33 IFNG IL10 IL4
30 synaptic transmission, cholinergic GO:0007271 9.26 CHRNA1 CHRNE CHRNG RAPSN
31 immune response GO:0006955 9.23 CTLA4 IFNG IL10 IL2 IL4 MBP

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.62 MBP RYR1 TNF TTN
2 extracellular ligand-gated ion channel activity GO:0005230 9.58 CHRNA1 CHRNE CHRNG
3 ligand-gated ion channel activity GO:0015276 9.54 CHRNA1 CHRNE CHRNG
4 acetylcholine-gated cation-selective channel activity GO:0022848 9.43 CHRNA1 CHRNE CHRNG
5 cytokine activity GO:0005125 9.43 IFNG IL10 IL2 IL4 TNF TNFSF13B
6 acetylcholine receptor activity GO:0015464 9.33 CHRNA1 CHRNE CHRNG
7 acetylcholine binding GO:0042166 8.92 ACHE CHRNA1 CHRNE CHRNG

Sources for Myasthenia Gravis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....